Abstract
Advances in genetic engineering in the past decade have accelerated the expression, in plants, of foreign proteins with industrial and pharmaceutical value. Antigens from infectious bacterial or viral diseases have been introduced into plants through plant virus-mediated infection or Agrobacterium tumefaciens-mediated stable transformation methods. Oral immunization with transgenic plant tissues that contain vaccine antigen proteins stimulates both systemic and mucosal immune responses in animals. Plant-based vaccines can provide significant levels of protection against challenge by viral or bacterial pathogens.
Similar content being viewed by others
References and Recommended Reading
Mason HS, Lam DM, Arntzen CJ: Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992, 89:11745–11749.
Mason HS, Arntzen CJ: Transgenic plants as vaccine production systems. Trends Biotech 1995, 13:388–392.
Ma JCK, Vine ND: Plant expression system for the production of vaccines. Curr Top Microbiol Immunol 1999, 236:275–292.
Tsafrir S, Mor KE, Miguel A, et al.: Perspective: edible vaccines—a concept coming of age. Trends Microbiol 1998, 6:449–453.
Arntzen CJ: High-tech herbal medicine: plant-based vaccines. Nat Biotech 1997, 15:221–223.
Moffat SA: Exploring transgenic plants as a new vaccine source. Science 1995, 268:658–660.
Arntzen CJ: Pharmaceutical foodstuffs—oral immunization with transgenic plants. Nat Med Vaccine Suppl 1998, 4:1–2.
McGarvey PB, Hammond J, Dienelt MM, et al.: Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 1995, 13:1484–1487.
Hiatt A, Cafferkey R, Bowdish K: Production of antibodies in transgenic plants. Nature 1989, 342:76–78.
Schouten A, Roosien J, van Engelen FA, et al.: The C-terminal KDEL sequence increases the expression level of a singlechain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. Plant Mol Biol 1996, 30:781–793.
Ma JKC, Hiatt A, Hein MB, et al.: Generation and assembly of secretory antibodies in plants. Science 1995, 268:716–719.
Beachy RN, Fitchen JH, Hein MB: Use of plant virus for delivery of vaccine epitopes. Ann N Y Acad Sci 1996, 792:43–49.
Turpen TH, Rein SJ, Charoenvit Y, et al.: Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology 1995, 13:53–57.
Usha R, Rohll JB, Spall VE, et al.: Expression of an animal virus antigenic site on the surface of a plant virus particle. Virology 1993, 197:366–374.
Carrillo C, Wigdorocitz A, Oliveros JC, et al.: Protective immune response to foot and mouth disease virus with VP1 expressed in transgenic plants. J Virol 1998, 72:1688–1690.
Porta C, Spall VE, Loveland J, et al.: Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 1994, 202:949–955.
Dalsgaard K, Uttenthal A, Jones TD, et al.: Plant-derived vaccine protects target animals against a viral disease. Nat Biotech 1997, 15:248–252. This is the first report of a plant-derived vaccine that protects the target animal against an infectious disease.
Yusibov V, Modelska A, Steplewski K, et al.: Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci U S A 1997, 94:5784–5788.
Curtiss R, Cardineau GA: Oral immunization by transgenic plants. In US and International patents PCT/US89/03799. 1990.
Thanavala Y, Yang YF, Lyons P, et al.: Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci U S A 1995, 92:3358–3361.
Zhang RG, Scott DL, Westrook ML, et al.: The threedimensional crystal structure of cholera toxin. J Mol Biol 1995, 251:563–573.
Arakawa T, Chong DK, Merritt JL, Langridge WH: Expression of cholera toxin B subunit ologomers in transgenic potato plants. Transgenic Res 1997, 6:403–413. First-time demonstration of the assembly of cholera toxin pentamer structure in transgenic plants.
Arakawa T, Chong DK, Langridge WH: Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat Biotech 1998, 16:292–297. This study is the first time that it has been demonstrated that a bacterial toxin produced in plants could protect mammals against the toxin by feeding the transformed plant tissues.
Lycke N, Holmgren J: Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986, 59:301–308.
Jackson RJ, Fujihashi K, Xu-Amano J, et al.: Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993, 61:4272–4279.
Arakawa T, Yu J, Chong DK, et al.: A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotech 1998, 16:934–938. Food plants are feasible production and delivery systems for immunotolerization against autoimmune diseases.
Haq TA, Mason HS, Clements JD, Arntzen CJ: Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995, 268:714–716.
Tacket CO, Mason HS, Losonsky G, et al.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998, 4:607–609.
Mason HS, Ball JM, Shi JJ, et al.: Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996, 93:5335–5340. Virus capsid proteins can assemble into VLPs in plants that are immunogenic in mice.
Fiedler U, Conrad U: High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds. Biotechnology 1995, 13:1090–1093.
Hajishengallis G, Hollingshead AK, Koga T, Russell MW: Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995, 154:4322–4332.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yu, J., Langridge, W.H.R. Novel approaches to oral vaccines: Delivery of antigens by edible plants. Curr Infect Dis Rep 2, 73–77 (2000). https://doi.org/10.1007/s11908-000-0091-z
Issue Date:
DOI: https://doi.org/10.1007/s11908-000-0091-z